Skip to main content
OpenTrials
Completed

NCT Number: NCT02583243

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively follow everyone enrolled in buprenorphine care for as long as the individual takes buprenorphine to track the success of buprenorphine for the maintenance of opiate dependence.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The investigators propose to create a prospective cohort that will track outcomes for an opiate dependent population on buprenorphine maintenance. Individuals who have already decided to undergo buprenorphine treatment in Project BEST will be invited to participate in the following data collection process. The investigators propose the following series of data collection to assess clients during their time in the cohort:

GPRA, supplemental instrument, ASI, SCID, COWS, Urine toxicology.

Patients who are enrolled will enter a standardized, manual based weekly counseling regimen. Urine toxicology will be performed a minimum of twice monthly, but will not occur at the same times monthly to decrease the probability of sampling error.

This is a prospective cohort to follow a group of individuals on buprenorphine treatment. The goal of this prospective cohort is to generate thoughtful observations. Specific items of interest which will be compared with age, race matched historical controls on methadone will be:

  • Changes in addiction severity over treatment time
  • Changes in sexual risk behaviors and injection practices
  • Improvements in urine toxicology
  • Co-occurring mental illness

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Opiate dependent by DSM IV criteria - to be determined by clinician - on buprenorphine through the Project BEST Program.

Exclusion criteria

  • Inability to adhere to study instruments.

Treatment and study plan

MET/CBT based individualized counseling

Behavioral

Manualized counseling with the first four week being MET followed by 8 weeks of CBT

buprenorphine

Drug

Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Important dates

Study start
2005
Primary completion
2008
Study completion
2008
First posted
Oct 22, 2015
Registry last updated
Apr 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.